[A comprehensive interdisciplinary view at the Return to Sport after COVID-19 infection].

The COVID-19 pandemic has affected the whole world. It applies to all age and social groups. It is no different with athletes.

[AT1 blockers - comparability with ACE inhibitors].

The reduction in overall mortality, cardiovascular mortality and the occurrence of myocardial infarction in patients treated with AT1 blockers is comparable with the use of ACE inhibitors. In addition, there is a lower proportion of AT1 blockers withdrawal of treatment due to adverse reactions.Key words: ACE inhibitors - AT1 blockers - cardioprotection - hypertension - renin-angiotensin-aldosteron system.

[The results of SPRINT study from the point of nephrology].

There is no consensus of the opinion that the value of systolic blood pressure (SBP) is the most favourable for the treatment of hypertension in patients with chronic kidney disease (CKD). The interventional study SPRINT (The Systolic Blood Pressure Intervention Trial) demonstrated the significant reduction in major cardiovascular events and overall mortality with intensive control of SBP (< 120 mm Hg) in individuals with high risk, including those with CKD and mild proteinuria. Nephrologists should take into account the results of the SPRINT study in the determination of the optimal SBP in patients with CKD, but at the same time they pay the attention to the early detection of adverse events related to treatment, including disorders of electrolyte balance, acute renal impairment, hypotension, and side effects of medications.